Size Matters: Unlocking the Genetic Secrets of Pediatric Lymphatic Malformations
"New research reveals significant gene expression differences between microcystic and macrocystic lymphatic malformations, paving the way for targeted treatments."
Lymphatic malformations (LMs) are congenital vascular anomalies that appear as dilated, cyst-like channels. Doctors classify them as either macrocystic (large cysts) or microcystic (small cysts). But beyond size, these two types behave differently, respond to treatment differently, and ultimately have different prognoses. This suggests that something more than just physical size dictates their behavior.
To understand what drives these differences, a team of researchers delved into the genetic makeup of LMs. They hypothesized that the distinct clinical characteristics of macrocystic and microcystic LMs stem from variations in their underlying biology and genetic influences.
By analyzing gene expression in a small sample of LM subtypes, the researchers identified a significant number of genes that are expressed differently between macrocystic and microcystic LMs. This discovery opens new avenues for understanding and potentially treating these complex conditions.
How Lesion Size Shapes Lymphatic Malformations
Microcystic lymphatic malformations (LMs) consist of cysts smaller than 1 cm and often appear at birth or during the first years of life; they most often affect the head and neck, though they can occur elsewhere. Their symptoms depend on the lesion’s location and extent. Unlike macrocystic LMs, which have large fluid-filled cysts, microcystic LMs can have a sponge-like appearance. The size of microcysts makes treatment challenging, while percutaneous sclerotherapy has been shown to be effective for macrocystic LMs.
Treatment Depends on LM Subtype
Lymphatic malformations are slow-flow vascular anomalies that can include microcysts, macrocysts, and a dilated lymphatic system that does not communicate with normal lymphatic drainage. Treatment goals include controlling symptoms and reducing the anomaly’s overall size. Percutaneous sclerotherapy is established for macrocystic LMs, but microcystic lesions remain challenging to treat because of their small size. A retrospective analysis of prospectively collected data has examined bleomycin infusion using a lymphographic-like technique in patients whose MRI showed at least one microcystic component.
Two Types, Two Genetic Profiles
The study revealed that microcystic LMs tend to exhibit a gene expression pattern that promotes cancer-like activity. This includes the upregulation of genes targeted by MYC, a known oncogene, as well as genes involved in cell cycle progression. In simple terms, microcystic LMs show a genetic signature that encourages cell growth and proliferation.
- Microcystic LMs: Upregulation of MYC target genes, cell cycle proteins, and anti-apoptotic mechanisms, mirroring oncogenic pathways.
- Macrocystic LMs: Gene expression indicating hypoxic conditions, leading to angiogenesis and cell proliferation.
- Common Ground: While distinct, both types ultimately result in increased cell proliferation, highlighting a shared characteristic despite differing pathways.
Molecular Clues to Lesion Differences
A review of genetic and molecular determinants reports that increased expression of the metastatic suppressor NME1 may limit cell spreading and motility, potentially helping explain the condensed, fibrous morphology of microcystic LMs. Separately, a report on thoracic complex lymphatic anomalies notes prior findings linking cyst size with gene-expression profiles in the PI3K-AKT-MTOR pathway. A decade-long, single-center retrospective study of pediatric LMs points to molecular biology as a possible way to investigate differences across lesion locations and subtypes, while noting that its findings do not directly explain the site-specific distribution.
Different Lesion Sizes, Different Treatment Challenges
Percutaneous sclerotherapy has been used effectively for macrocystic LMs, whereas treating microcystic LMs remains challenging because of their size. A 2024 article introduces intralesional laser thermolysis (ILT) for microcystic lesions. Its conclusion describes ILT combined with traditional sclerotherapy as safe, feasible, and effective, including in a treatment context involving polidocanol and pingyangmycin. The supplied sources also describe sirolimus as an option for microcystic LMs, but do not provide comparative outcome figures for it.
What This Means for Treatment
The discovery of distinct genetic profiles for microcystic and macrocystic LMs has significant implications for treatment strategies. Understanding the underlying mechanisms driving each type of malformation could lead to more targeted and effective therapies.
Lymphatic Malformations Across Conditions
Lymphatic malformations can occur in isolation as cystic LMs, generalized lymphatic anomaly (GLA), kaposiform lymphangiomatosis (KLA), or Gorham-Stout disease. They can also form part of combined vascular malformations that include capillary, venous, and arteriovenous malformations. This broader range of presentations places cystic LMs within a wider group of lymphatic and vascular conditions.
Evaluating Treatment in Children
A real-world study assessed the effectiveness and safety of oral sirolimus for lymphatic malformations in the head and neck. Its authors note that earlier sirolimus studies were single-arm clinical trials and that some LM lesions can shrink spontaneously, potentially complicating the assessment of treatment effects. A 2024 systematic review identifies persistent variation in how children’s LMs are managed and sets out to summarize outcomes for medical therapy, sclerotherapy, and surgery and provide evidence-based recommendations. The supplied excerpts do not report specific comparative outcomes.
For example, microcystic LMs, with their oncogenic-like profile, might respond to therapies that target MYC or cell cycle progression. Macrocystic LMs, driven by hypoxia and angiogenesis, could be treated with anti-angiogenic drugs or interventions that improve oxygen supply to the affected tissues.
While more research is needed, this study represents a crucial step forward in understanding the complexities of lymphatic malformations and developing personalized treatments that address the unique characteristics of each LM subtype. This can eventually lead to less invasive and more promising results.